Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $91. The company’s shares opened today at $39.37.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.8% and a 33.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $57.45, representing a 45.9% upside. In a report issued on January 17, Piper Jaffray also reiterated a Buy rating on the stock with a $55 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $55 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 556.8K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2018, David Stack, the CEO & Chairman of PCRX bought 12,000 shares for a total of $42,600.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
